Publications
PUBLICATIONS
MiraKind is working to further identify ways to preserve health and prevent cancer for individuals with the KRAS-variant and other genetic variants like it.
Significant published research related to the KRAS-variant:
2021
Association between rs61764370, rs9266, and rs140080026 polymorphisms of the KRAS gene and breast cancer risk in a Mexican population
M P Gallegos-Arreola, P M García Verdín, M T Magaña-Torres, L E Figuera, G M Zúñiga-González, M A Rosales-Reynoso, B C Gómez-Meda, A M Puebla-Pérez Eur Rev Med Pharmacol Sci. 20Nov;25(21):6454-6464. PMID: 34787849
2020
Association of Rs61764370 polymorphism within let-7 microRNA-binding site with lung cancer in Iranian population
Neda Farokhzad, Sayed Mostafa Hosseini, Houri Edalat, Morteza Sadeghi
Afr Health Sci. 2020 Sep;20(3):1299-1303. PMID: 33402978
2019
MicroRNA-binding site polymorphisms and risk of colorectal cancer: A systematic review and meta-analysis
Morteza Gholami, Bagher Larijani, Farshad Sharifi, Shirin Hasani-Ranjbar, Reza Taslimi, Milad Bastami, Rasha Atlasi, Mahsa M Amoli, Cancer Med. 2019 Dec;8(17):7477-7499. doi: 10.1002/cam4.2600. PMID: 31637880
Lack of an Association between a Polymorphism in the KRAS 3' Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study
Thomas M D'Hooghe, Olga Grechukhina, SiHyun Cho, Amelie Fassbender, Dorien O, Daniëlle Peterse, Joanne Weidhaas, Hugh S Taylor, Gynecol Obstet Invest. 2019;84(6):575-582. doi:10.1159/000500626. Epub 2019 Jun 11 PMID: 31185482
Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers
Vianney Bastit, Nicolas Bon-Mardion, Jean-Michel Picquenot, Vinciane Rainville, Cristian Moldovan, Arnaud François, Agnès Loeb, Sébastien Thureau, Dorel Manu, Fabrice Jardin, Jean-Paul Marie, Fréderic Di Fiore, Florian Clatot
Eur Arch Otorhinolaryngol. 2019 Feb;276(2):541-550. doi: 10.1007/s00405-018-5235-6. PMID: 30523411
2017
Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis
E K Morgen, H-J Lenz, D J Jonker, D Tu, G Milano, F Graziano, J Zalcberg, C S Karapetis, A Dobrovic, C J O'Callaghan, G Liu
Pharmacogenomics J. 2017 Dec;17(6):535-542. doi: 10.1038/tpj.2016.56. PMID: 27897268
KRAS Gene Polymorphisms and their Impact on Breast Cancer Risk in an Iranian Population
Sanaei S, Hashemi M, Eskandari E, Hashemi SM, Bahari G.
Asian Pac J Cancer Prev. 2017 May 1;18(5):1301-1305.
PMID: 28610418
The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. JAMA Oncol. 2017 Apr 1;3(4):483-491. doi: 10.1001/jamaoncol.2016.5478. PMID: 28006059
2016
A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.
Kazmi HR, Chandra A, Kumar S, Satyam LK, Gupta A, Nigam J, Srivastava M, Mittal B.
J Cancer Res Clin Oncol. 2016 Sep 12.
Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J, Seijas-Tamayo R, Mesía R, Taberna M, Pastor Borgoñón M, Pérez-Ruiz E, Adansa Klain JC, Vázquez Fernández S, Del Barco Morillo E, Lozano A, González Sarmiento R, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).
Oral Oncol. 2016 Dec;63:38-43. doi: 10.1016/j.oraloncology.2016.10.006. Epub 2016 Nov 12. PMID: 27938998
A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells.
Zhang S1, Hou C1, Li G1, Zhong Y1, Zhang J1, Guo X1, Li B2, Bi Z1, Shao M1.1., Int J Mol Med. 2016 Sep;38(3):919-26. doi: 10.3892/ijmm.2016.2661. Epub 2016 Jul 4.
The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women.
Gutiérrez-Malacatt H, Ayala-Sanchez M, Aquino-Ortega X, Dominguez-Rodriguez J, Martinez-Tovar A, Olarte-Carrillo I, Martinez-Hernandez A, C CC, Orozco L, Cordova EJ. Asian Pac J Cancer Prev. 2016;17(4):2265-70. PMID: 27221928, Free Article, Similar articles, Select item 26710843
KRAS polymorphisms are associated with survival of CRC in Chinese population.
Dai Q, Wei HL, Huang J, Zhou TJ, Chai L, Yang ZH., Tumour Biol. 2016 Apr;37(4):4727-34. doi: 10.1007/s13277-015-4314-1. Epub 2015 Oct 29., PMID: 26515332, Similar articles, Select item 26162609
2015
Impact of KRAS variant rs61764370 on breast cancer morbidity.
Ustinova M, Daneberga Z, Bērziņa D, Nakazawa-Miklaševiča M, Maksimenko J, Gardovskis J, Miklaševičs E., Exp Oncol. 2015 Dec;37(4):292-4., PMID: 26710843, Similar articles, Select item 26573509
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Ganzinelli M, Rulli E, Caiola E, Garassino MC, Broggini M, Copreni E, Piva S, Longo F, Labianca R, Bareggi C, Fabbri MA, Martelli O, Fagnani D, Locatelli MC, Bertolini A, Valmadre G, Pavese I, Calcagno A, Sarobba MG, Marabese M., Sci Rep. 2015 Nov 17;5:16331. doi: 10.1038/srep16331., PMID: 26573509, Free PMC Article, Similar articles Select item 26515332
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N., Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10., PMID: 26162609, Similar articles, Select item 26077004
Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
Uvirova M, Simova J, Kubova B, Dvorackova N, Tomaskova H, Sedivcova M, Dite P., Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):466-71. doi: 10.5507/bp.2015.029. Epub 2015 Jun 11., PMID: 26077004, Free Article, Similar articles, Select item 25987236
Functional variants in CYP1B1, KRAS and MTHFR genes are associated with shorter telomere length in postmenopausal women.
Cerne JZ, Pohar-Perme M, Cerkovnik P, Gersak K, Novakovic S., Mech Ageing Dev. 2015 Jul;149:1-7. doi: 10.1016/j.mad.2015.05.003. Epub 2015 May 15., PMID: 2598723, Similar articles, Select item 25940428
Estrogen Withdrawal, Increased Breast Cancer Risk and the KRAS-variant.
McVeigh TP et al. Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11. PMID: 25961464 Free PMC Article Similar articles Select item 25940428
Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis.
Farahani MS, Shahbazi S, Moghaddam SA, Mahdian R., Reprod Sci. 2015 Jun;22(6):679-84. doi: 10.1177/1933719114556478. Epub 2014 Oct 30., PMID: 25361550, Free PMC Article, Similar articles, Select item 25183481
2014
The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J., PLoS One. 2014 Apr 14;9(4):e94167. doi: 10.1371/journal.pone.0094167. eCollection 2014., PMID: 24732316 Free PMC Article, Similar articles, Select item 23083368
The involvement of KRAS gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.
Ying HQ, Wang F, He BS, Pan YQ, Gao TY, Xu YQ, Li R, Deng QW, Sun HL, Wang SK., Onco Targets Ther. 2014 Aug 25;7:1487-96. doi: 10.2147/OTT.S65496. eCollection 2014., PMID: 25210463 Free PMC Article, Similar articles, Select item 25183481
A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S., Clin Cancer Res. 2014 Sep 1;20(17):4499-510. doi: 10.1158/1078-0432.CCR-14-0348., PMID: 25183481 Free PMC Article, Similar articles, Select item 2511458
MicroRNA binding site polymorphisms as biomarkers in cancer management and research.
Cipollini M, Landi S, Gemignani F., Pharmgenomics Pers Med. 2014 Jul 23;7:173-91. doi: 10.2147/PGPM.S61693. eCollection 2014. Review., PMID: 25114582, Free PMC Article, Similar articles, Select item 25081901
A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH et al. Ann Oncol. 2014 Nov;25(11):2230-6. doi: 10.1093/annonc/mdu367. Epub 2014 Jul 31.
A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
De Ruyck K, Duprez F, Ferdinande L, Mbah C, Rios-Velazquez E, Hoebers F, Praet M, Deron P, Bonte K, Speel EJ, Libbrecht L, De Neve W, Lambin P, Thierens H., Cancer Epidemiol. 2014 Oct;38(5):591-8. doi: 10.1016/j.canep.2014.07.008. Epub 2014 Aug 12., PMID: 25127693, Similar articles, Select item 24932237
SLC23A2-05 (rs4987219) and KRAS-LCS6 (rs61764370) polymorphisms in patients with squamous cell carcinoma of the head and neck.
Santiago MB, DE Lima Marson FA, Secolin R, Ribeiro JD, Lima CS, Bertuzzo CS., Oncol Lett. 2014 Jun;7(6):1803-1811. Epub 2014 Apr 3., PMID: 24932237 Free PMC Article, Similar articles, Select item 24890702
Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
Langevin SM, Christensen BC., Cancer Med. 2014 Oct;3(5):1385-95. doi: 10.1002/cam4.279. Epub 2014 Jun 2. Review., PMID: 24890702 Free PMC Article, Similar articles, Select item 24282149
Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB., Clin Cancer Res. 2014 Jun 15;20(12):3319-27. doi: 10.1158/1078-0432.CCR-14-0069. Epub 2014 Apr 11., PMID: 24727325 Free PMC Article, Similar articles, Select item 23324806
2013
Targeted Knock-in of the Polymorphism rs61764370 does not Affect KRAS Expression but Reduces let-7 Levels
Crowley EH et al. Hum Mutat. 2013 Nov 26.
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients
Sebio A et al. Pharmacogenet Genomics. 2013 Mar;23(3):142-7.
2012
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH., BMC Cancer. 2012 Nov 20;12:534. doi: 10.1186/1471-2407-12-534., PMID: 23167843 Free PMC Article, Similar articles, Select item 23010532
No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.
Luong HT, Nyholt DR, Painter JN, Chapman B, Kennedy S, Treloar SA, Zondervan KT, Montgomery GW., Hum Reprod. 2012 Dec;27(12):3616-21. doi: 10.1093/humrep/des329. Epub 2012 Sep 25., PMID: 23010532 Free PMC Article, Similar articles, Select item 22679560
KRAS-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
Caiola E, Rulli E, Fruscio R, Buda A, Broggini M, Marabese M., Am J Cancer Res. 2012;2(3):298-308. Epub 2012 Apr 21., PMID: 22679560 Free PMC Article, Similar articles, Select item 22662244
KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter
Ryan BM, et al. Clin Cancer Res. 2012 Jun 15;18(12):3487-8; author reply 3489.
A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis
Grechukhina O., et al. EMBO Mol Med. 2012 Mar;4(3):206-17.
High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease
Ruzzo A et al. Oncologist. 2012;17(6):823-9.
SNPing cancer in the bud: MicroRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer
Salzman & Weidhaas., Pharmacol Therapy, 2012.
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer
Pilarski et al., PLoS One, 2012.
KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel
Kundu ST et al. Cell Cycle. 2012 Jan 15;11(2):361-6.
2011
A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer
Ratner E. et al. Oncogene. 2011 Dec. 5.
A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer
Kim M. Smits et al. Clin Cancer Research, 2011, Oct 12.
MicroRNA signatures differentiate melanoma subtypes
Chan E. et al. Cell Cycle. 2011 Jun1:10(11):1845-52.
KRAS rs61764370 in Epithelial Ovarian Cancer-Letter
Joanne B. Weidhaas and Frank J. Slack. Clinical Cancer Research. Accepted May 31, 2011.
A 3’ untranslated region KRAS variant and triple-negative breast cancer: a case control and genetic analysis
Paranjape T. et al. Lancet Oncology. 2011 Apr;12(4):377-86.
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D; BCFR Investigators, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dörk T, Dürst M, Eccles DM, Ekici AB, Easton D; EMBRACE Investigators, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O; GEMO Study Collaborators, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M; HEBON Investigators, Heikkinen T, Hein R, Høgdall C, Høgdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G; kConFab Investigators and the Consortium of Investigators of Modifiers of BRCA1/2, Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, Lapolla JP, Lázaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Lindblom A; SWE-BRCA Investigators, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA; Ovarian Cancer Association Consortium., Clin Cancer Res. 2011 Jun 1;17(11):3742-50. doi: 10.1158/1078-0432.CCR-10-3405. Epub 2011 Mar 8., PMID: 21385923 Free PMC Article, Similar articles, Select item 20676756
KRAS Let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?
Zhang W. et al. Ann Oncol. 2011 Feb 22(2):484-5.
2010
Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan
Graziano F et al. Pharmacogenomics J. 2010 Oct;10(5):458-64.
Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients
Ruzzo A et al. Ann Oncol. 2010 Oct 6.
KRAS Mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer
Nelson HH et al. Lung Cancer. 2010 Jul;69(1).
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk
Ratner E et al. Cancer Res. 2010 Aug 15;70(16):6509-15.
Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families
Hollestelle A et al. Breast Cancer Res Treat. 2011 Jul 30.
The KRAS-Variant Genetic Test As a Marker of Increased Risk of Ovarian Cancer
Keane FK and Ratner ES. Rev Obstet Gynecol. 2010 Summer;3(3):118-21.
2009
The BRCA1 3’-UTR: 5711þ421T=T_5711þ1286T=T Genotype Is a Possible Breast and Ovarian Cancer Risk Factor
Malinee Pongsavee et al. GENETIC TESTING AND MOLECULAR BIOMARKERS. Volume 13, Number 3, 2009 Mary Ann Liebert, Inc. Pp. 307-317.
A let-7 microRNA-binding site polymorphism in the KRAS 3′ UTR is associated with reduced survival in oral cancers
Christensen BC et al. Carcinogenesis. 2009 Jun;30(6):1003-7.
2008
A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk
Chin LJ, Ratner E et al Cancer Res. 2008 Oct 15;68(20):8535-40.
